Animal study · mice
Retatrutide eased diet-induced steatohepatitis in female mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
Adds early mouse evidence that retatrutide can reduce diet-driven fatty liver inflammation, shown in female mice, not yet a human finding.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2025
- Journal
- Am J Physiol Gastrointest Liver Physiol
What they tested
The team set out to build a shorter mouse model of diet-driven steatohepatitis (fatty liver with inflammation) and to test whether retatrutide improves it.
How the study was done
A study in female and male C57BL/6N mice that got either one fructose binge of 10 mg/g body wt or a new 31-day plan of a Western diet, fructose and sucrose in their water, and a last fructose binge. In the 31-day plan, mice got retatrutide or a vehicle (an inactive control treatment) over the final 2 weeks.

Model. Individual results vary.
What they found
In mice, one fructose binge raised ALT (a liver enzyme that signals liver injury) and liver triglycerides in females after 6 h, while males showed less liver harm. The 31-day plan raised body weight, ALT, liver triglycerides and cholesterol, and liver inflammation markers in both sexes compared with chow-fed mice. Its liver gene pattern from RNA sequencing lined up with human MASH in children and adults. In female mice, retatrutide over the last 2 weeks lowered body weight, ALT, liver triglycerides and cholesterol, and liver inflammation markers compared with vehicle-treated mice.
What it doesn’t show
This is mouse work, not a human result, and the retatrutide benefit is reported for female mice. The treatment ran only 2 weeks in a short 31-day model.
The paper
Viebahn et al. Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. Am J Physiol Gastrointest Liver Physiol. 2025.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.